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A P. REYHACH and A Vernikos, AG'W-liko peptides inaroase
pain sensitivity and antagonise opiate analgesia, European
A Pharmacol. 00(1980)000-000.
The role of the pituitary and of ACTH in pain sensitivity was
investigated in the rat. pain sensitivity was assessed by measuring
paw-lick and ,dump latencies in response to being placed on a grid at
55 0 C. Eypophysectomy reduced pain sensitivity, and this affect was
reversed by the Intracerebroventricular (1CV) injection of the opiate
antagonist naloxone. Similarly, the analgesia produced by a dose of
morphine was antagonized by the administration of ACTH or a--MSH. The
peripheral in;jectlon of ACTU or a-MSH in normal rats slid not increase
pain sensitivity, However, ACTH administered TCV increased pain sensi-
tivity within 10 min. The results indicate that toe pituitary is the
source of nn endogenous opiate antagonist and hyp+eralgesic factor and
that this ;factor is ACTU or an ACTT-like peptide. This activity resides
A the N--terminal portion of the ACTH molecule since ACTH4.10 is not
active in this respect, nor does this activity require a :free N-terminal
serin+e since o-MSH appears to be almost as potent as the AC` Ul-24
peptide. It is concluded that ACTH-Like peptides of pituitary origin
act as endogenous hyperalgosi.c and opiate antagonistic factors.
Adrenocorticotropin-like peptides 	 Opiate antagonism 	 .
Hyperalgesia
	
Hypophysectomy
1. Introduction
Adrenocorticotrophict hormone (ACTH) and structurally related
peptides exert profound influences on a wide range of behaviors
(De Died, 1977) and on brain function (Vernikos-Danellis, 1972). We
have recently demonstrated that pain sensitivity could be altered Sig-
nificantly by physiological manipulaH gin of endogenous levels of
pituitary-adrenocortical hormones (Heybach and Vernikos- Danelli,s, 1978).
Increased sensitivity to pain was correlated with increased circulating
levels of ACTH, but was independent of any direct influence of circulat-
ing corticosteroids. Bases on, these findings we proposed a direct
neuromodulatory role for ACTT in pain perception mechanisms. The site
or sites of action of such a role for ACTH are not known, however, in
in vitro brain homogenate preparations, ACTH antagonizes morphine bind-
ing to opiate receptors (Terenius et al., 1975) and is capable of dis-
placing S-endorphin binding (Akii et al., 1980) suggesting that the
likely site of action of ACTH is on opioid receptors in the central
nervous system (CNS).
In the present series of experiments we investigated the hypothesis
that the pituitary is the source of an endogenous opioid antagonist and
that this substance is ACTH or an ACTH-Like peptide. We further de pion-
strated that unlike nal.oxone the intracerebroventri.cul.ar administration
of ACTH I-39 (the complete peptide sequence), ACT111-24 , and the struc-
turally related peptide a-mel,anocyte stimulating hormone (a-MSH) are
capable of increasing the sensitivity to pain in normal animals by a
direct action on the CNS.
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2. Materials and methods
Male Sprague Dawley rats (Simonsen Laboratories, Gilroy,
California) weighing 205 t10 g, were used. They were 'housed Five: per
cage in large plastic, top--loading cagee g
 with wood-chip bedding. Rats
had ad libitum access to standard laboratory chow and water, They were
kept on a 12-h light-dark schedule (lights on at 0700) and the tempera-
tore was maintaJAied at 23 t3°C. Groups of at least eight animals were
used for each experimental condition.
Drugs used and their suppliers were as fol,lowa: ACTH was obtained
from Armour Laboratories, Kankakee, Illinois; ACT11 1 _24 , ACT114-10, and
o-MSH were obtained rom Bachem Inc., Torrance, California; and morphine
and naloxone were obtained from Endo Laboratories, Garden City, New York..
Doses of morphine and naloxone were calculated as the free base.
Hypophysectomies were performed under ether anesthesia, using the
transauricular approach with the animal in a stereota4xic instrument
(Heybach and Venikos-Danellis, 1978). ;Animals were provided with 5%
dextrose instead of drinking water and were used 1 day postsurgery.
Intraventricular c:annulations were done according to the method
of Severs et al. (1970), under pentobarbital anesthesia (50 mg/kg i.p.).
Cannulas constructed from disposable 20-gauge hypodermic needles, filled
with silastic, were implanted 1 mm caudal to the coronal suture and
1.5 mm lateral to the midsagittal suture.. They were secured to the skull
with acryllic cement. Substances to be injected intraventricularly were
dissolved in 0.9% saline immediately before use. Animals received
either intraventricular injections (2 Ul) of saline, the peptides, or
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naloxone in 2 ul saline. Injections were made with Hamilton microliter
syringes fitted with a stop to prevent the needle from passing beyond
the tip of the cannula. Animals were tested for pain sensitivity at
10, 20, and 30 min after an ivt injection. At the completion of all
experiments, 5 u1 of blue ink was injected through the cannula before
sacrificing the animal. Brains were examined to ensure that the dye was
•
`	 distributed throughout the ventricular space.
The apparatus used to assess sensitivity to pain has been described
previously (Heybach and Vernikos-Mnellls, 1978). The procedure for
estimating pain sensitivity was standardized for all experiments. All
animals were initially allowed three 90-sec sessions (one session per
day for 3 ct)nsecutive days) in the testing chamber with the temperature
of the ,floor maintained at 23 it°C. Thim procedure familiarized the
ruts with handling and allowed for habituation to the novelty of the
apparatus. To initiate testing, the rat was placed on the grid :floor
of the apparatus, maintained at 55 WC, and a stopwatch was started.
Two responses were Chen recorded: the latency to lift from the floor
and lick one paw (i.e., paw-lick latency), and subsequently the latency
to show a jump response consisting of vigorously lifting both hind paws
off the grid floor simultaneously (1.e. 0 jump latency). The paw-lick
and jump latencies were used as indices of sensitivity to the painful
stimulus. During testing, the experimenter was not aware of the condi-
Y
tion of the rat being tested. If neither a paw-lick nor a jump response
was made in 9C sec, the test was terminated and a latency of 90 sec was
recorded for each response. All testing was carried out between 0800 and
1200 h.
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Statistical analysis of the response, latencies was carried out
using one-way analyses of variance for relevant two-group comparisons.
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w	 3. Results	 1'
Figure 1 shows the paw-lick and jump latencies of rata that had
been hypophyseetomized or sham
-hypophysectomized and injected intraven-
tricularly with either saline or naloxone. Hypophysectomy increased the
latency of both responses. Whereas naloxone had no significant effect
on the responses of the sham-hypophysectomized animals, it antagonized
the analgesic effect of hypophysectomy and restored the pain sensitivity
of the hypophysectomized rats to normal.
Since opiate antagonist properties of the pituitary were implied
by this and previous data, and since the changes in pain sensitivity
after adrenalectomy correlated well with the changes in circulating ACTH
(Heybach and Vernikos-Danellis, 1978), we studied the effect of ACTH and
a-MSH on the analgesic action of morphine!. Rats injected with a dose of
3 mg/kg morphine ( i. p. ) were given,
 30 min later, a second injection of
either saline, a-MSH, or ACTH (i.p.) and tested for paw-lick and jump
responses. Figure 2 shows that 10 utin after the injections of these
peptides, this dose of m^irphine produced only half of its usual analgesic
effect. Antagonism of morphine ' s analgesic action was even greater 20 or
30 min after ACTH injection. It should be noted, however, that the con-
trol injection of saline also antagonized the morphine effect to some
extent; this was particularly evident in the paw -lick response.
Figure 3 shows that the peripheral administration of ACTH or a-MSH
alone did not alter either the paw-lick or the jump latency of normal,
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rats. However, after intracerebroventricular (ICS ►) administration,
ACTH1-24 or a-HSH markedly reduced the paw-lick and the jump latencies
at doses that were one fourth of those that were ineffective when given
peripherally (fig. 4). ACTH4-10 had no effect on pain sensitivity.
4. Discussion
We have recently obtained evidence that ACTH may be a critical
pituitary factor involved in mediating the perception of pain (Heybach
and Vernikos, 1978). We found that whereas sensitivity to pain was
unaltered 3 days after adrenalectomy when circulating corticosterone
was absent and ACTH levels were low, animals adrenalectomized for 9 or
18 days, when plasma ACTH levels were significantly increased, showed
a marked increase in pain sensitivity as well. In contrast, removal of
the pituitary gland led to a prompt decrease in pain sensitivity. Such
a decrease has also been observed in the clinical studies of Luft and
Olivecrona (1955). Based primarily on these results, we proposed that
ACTH or possibly some other pituitary ACTH-like peptide that is also
regulated by glucocorticoid negative feedback, may function as an
endogenous opioid antagonist, modulating pain sensitivity. If this
were the case, then synthetic opiate antagonists should reverse the
analgesia Ciat follows hypophysectomy, and the direct central adminis-
tration of ACTH should increase pain sensitivity and antagonize the
actions of opiates.
Our findings support this hypothesis. The ICV administration of
naloxone restored the pain sensitivity, of hypophysectomized rats to
normal, though it had no apparent effect in normal animals. Similarly,
7
►ICV-administered ACTH increased pain sensitivity. This increased sensi-
tivity or responsiveness to pain was apparent after ICV injections of
i crude ACTHl- 39 (Armour), ACTH1 -24, or a-MSH. Irtraperitoneal injections
of ACTH or u-MSH were ineffective in this respect even at doses that
were four times as great as those administered centrally. Therefore, it
't
appears that ACTH and .related peptides are capable of increasing sensi-
tivity to a painful stimulus by a direct effect on the central nervous
system and that they display some degree of structural specificity in
exerting this effect. The activity seems to reside in the N-terminal
portion of the molecule, whether the N-terminal Aerine is acetylated or
not. It is conceivable that larger, peripherally administered doses of
these peptides might also be able to increase pain sensitivity. How-
ever, although these peripheral doses themselves produced no change in
A
	
	
pain sensitivity, both ACTH and u-MSH were very effective in antagoniz-
ing the analgesic action of morphine. Such an effect of ACTH in antag-
onizing morphine-induced analgesia has been reported previously (Gispen
et 31., 1976; Paroli, 1967) but this work demonstrates that ACTH and
ACTH-like peptides can themselves directly increase pain sensitivity.
The finding that the peripheral injection of saline reduced the
`	 effect of morphine on pain sensitivit3 i but to a lesser extent and with
f
a somewhat different time course than either ACTH or a-MSH, is con-
sistent with the notion that the stressful nature of the injection pro-
cedure itself, via release of endogenous ACTH or related peptides from
the pituitary, can lead to antagotLtsm of morphine-induced analgesia
(Vernikos yet al., submitted to European J. Pharmacol., 1980).
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It is particularly interesting that the synthetic peptide fragment
ACTH4-10, which has no adrenocortical stimulating activity, had also no
effect on pain sensitivity when administer4d ICV, Similarly, it has
been reported that ACTH4_10 is ineffective in antagonizing morphine
induced analgesia in spite of its apparent affinity for rat brain opiate
receptors (Wegant et al., 1977). Thus, although the ample evidence for
interactions of ACTH with opiate receptors (Terenius et al., 1975) is
encouraging support for the hypothesis that ACTH exerts its hyperalgesic
effects and its opiate antagonistic effects by acting on opiate receptor
systems, the discrepancy between the receptor affinity and physiological,
action of ACTH4 - 10 suggests caution in extrapolating receptor -binding
data to physiological activity.
The presence of ejt^",'H in various areas of the central nervous system
has now been well documented (Orwall et al., 1979) although it is still
not clear what its source and function there might be (Krieger, 1980).
Nevertheless, our studies show that the pituitary is the primary source
of this ACT11-like peptide that exerts hyperalgesic and opiate antagonistic
effects; this is because hypophysectomy reduces pain sensitivity while
increases in pituitary and circulating ACTH, as a function of time after
adrenalectomy, result in a similar, time -dependent increase in the sensi-
tivity to pain (Heybach and Vernikos-Danellis, 1978).
In contrast, although the pituitary is also a rich source of endor-
phins, which have been shown to be secreted concomitantly with ACTH
(Bossier et al., 1980) 0 the primary function of this endogenous opiate
in the pituitary would not appear to be in pain suppression, since hypo-
physectomy should have been expected to result in increased . pain sensitivity.
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r is it likely that a compensatory increase in endorphin activity in
a CN5 would appear within 24 h of hypophysectomy. It is tempting to
ggest instea-°t chat its function there might be to modulate CRF, and
areby ACTH secretion * by a short feedback-loop effect on the hypo-
alamus. unlike met-enkephalin, which stimulates CRF secretion,
andorphin alone does not affect CRF secretion, but antagonizes the
stimulatory actions of morphine and enkephalin (Buckingham and Hodges,
1979). More recently, we have found that S- endorphin in concentrations
as low as 10-5 M antagonizes in a dose-dependent manner the acetylcholine
stimulated secretion of CRF from isolated hypothalami in vitrq (Buckingham
and Vernikos, unpublished observations).
The reversal of hypoalgesia, evident of 1 day following hypo-
physectomy, by the acute ICY administration of thx bynthetic opiate
antagonist naloxone, and the direct effect of ACTH and a-MSH in increas-
ing sensitivity to pain cnd in antagonizing morphine-induced analgesia,
lead us to suggest that under normal conditions sensitivity to pain
m,g',;c be regulated by a balance of endogenous opioids of central origin
and ACTH-like peptides of pituitary origin interacting at opiate receptor
sites.
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Fig. 1. Paw-liok (left) and dump ('right) 1a,tendi.es in hypophyr-2ctomiaed.
(cr-osehatched bars) and sh4*-hypop-hysectooixed (open bars) rata, after
intracerebroventricular injection of aaline (2 ul) or naloxone (2;0 ug).
Eaah column represents the mean *S.B. of the mean. (1) Sham-hypox,
Sal vs Hypox, Sal: pare lick 4 F(1,18) - 18.4 0
 p < 0.001; jump _..
F(1,18)	 12.6, p < 0.005. (2) Hypox, Sal vs Hypox, Nat: paw lick-
F(1,16) - 11.3, p < 0.01, Jump - F(1,17) . 21.3, p < 0.001.
Fig. 2. Percent change in latency of paw-link and jump responses of
morphine-treated rats (5 mg/kg i.p., 30 min previously) at 10, 20, and
30 min after an i.pt injection of saline, ACTH (Armour, 50 uU), or
a-MSH (50 p8).
Fig. 3. Paw-lick and jump latencies in response to i.p. injections of
saline, a-MSH, or ACTH.
Fig. 4. Paw-lick (left) and Jump .Latencies (right) in normal rats after
intracerebroventricular injection of saline (2 ul), ACTH1-24 (25 or
50 ug), ACTH4- 10 (25 Vg), or a-MSH (2.5 ug). (1) ACTH1-24 (25 ug) vs
Sal: paw lick ^- F(1,23) - 19.4, p < 0.005; jump - F(1,23) - 21.1,
I p < 0.001. (2) AC'TUI- 24 (50 ug) vs Sal: paw lick - F(1,26) - 20.3,
p < 0.005, Jump - x'(1,26) - 32.8, p < 0.001. (3) a-MSH vs Sal: paw
lick -° F(1,24) - 28.3, p < 0.001; jump - F(1,24) - 17.3 0 p < 0.005.
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